Close Menu

consumer genomics

The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.

Few Eyebrows Up

Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.

The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.

The project is informing participants of familial hypercholesterolemia genetic test results, and hereditary breast and ovarian cancer, and Lynch syndrome results will follow.

ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.

23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.

Indian DTC genomics company Mapmygenome has enlisted Israel-based Digital DNAtix to move its interpretation and personalized medicine services to a blockchain.

Researchers led by MD Anderson’s Karen Lu want to know the most efficient genetic counseling strategy as more people are getting screened for cancer risk genes.

Large-scale population sequencing projects and consumer genomics markets are picking up and oncology continues to be a strong market for Illumina.

With the help of AI, blockchain, and a new cryptocurrency, Nebula wants to give patients more control of their genomic data.

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.